What Deferasirox Treats: Main Uses and Benefits

Deferasirox is commonly used to help with managing chronic iron overload (hemosiderosis), a condition where excess iron accumulates due to chronic blood disorders requiring frequent transfusions, such as β-thalassemia, sickle cell disease (SCD), or myelodysplastic syndromes (MDS). The therapy is applied in contexts involving a heightened systemic burden of excess iron.

The medication helps with managing the resulting iron burden that accompanies necessary blood transfusions. The treatment helps address the risk of progressive organ damage caused by the systemic deposition of iron, particularly in the heart and liver. This supports the patient during difficult episodes by easing distress and assists with maintaining functional stability.

“The treatment is aligned with long-term management strategies and supports general well-being during symptomatic phases.”

The treatment may assist with easing the overall symptom load associated with high serum ferritin and Liver Iron Concentration (LIC). It is generally considered relevant in the supportive management of care for transfusion-dependent anemias across both adult and pediatric patient groups.

---

Quick Fact: Relief for Chronic Iron Overload

The treatment is applied in clinical settings that involve chronic, systemic imbalance and assists with maintaining functional stability in vital organs.

Regulatory References

1. European Medicines Agency (EMA) overview

The eligibility for Deferasirox is determined by age, underlying comorbidity status, and organ function, as defined in official regulatory labeling. Use is contraindicated in several specific populations.

Eligibility Scope

Classification	Population Rule (Official Regulatory Wording)
Contraindicated	Severe Renal Impairment: Estimated GFR lt 40 mL/min/1.73 m^2 or CrCl lt 40 mL/min.
Contraindicated	Platelet counts lt 50 imes 10^9/ L; poor performance status; high-risk MDS; or advanced malignancies.
Contraindicated	Severe Hepatic Impairment (Child-Pugh C).
Use Allowed (Age)	ge 2 years old for chronic iron overload due to blood transfusions; ge 10 years old for Non-Transfusion-Dependent Thalassemia (NTDT).
Use Restricted	Moderate Hepatic Impairment (Child-Pugh B) or Moderate Renal Impairment (CrCl 40–lt 60 mL/min).
Use Not Established	Children lt 2 years old for transfusional iron overload and lt 10 years old for NTDT.
Pregnancy/Lactation	May cause fetal harm based on animal data; not recommended during breastfeeding.

Official regulatory documents thus define strict limits on who can initiate therapy, prohibiting use when specific severe organ impairment or disease states are present, while mandating cautious use and monitoring in older adults.

Interactions with other medicines and products

Co-administration of Deferasirox with certain medicines and products is associated with documented interaction patterns defined by regulatory authorities.

---

Contraindicated Combinations and Restrictions

The official prescribing information formally contraindicates co-administration with aluminum-containing antacid preparations and other iron chelator therapies. The use of potent UDP-glucuronosyltransferase (UGT) inducers (such as rifampicin, phenytoin, or ritonavir) and Bile Acid Sequestrants (such as cholestyramine) should be avoided, as these substances significantly reduce the systemic exposure (AUC) of Deferasirox.

---

Pharmacokinetic and Pharmacodynamic Effects

Deferasirox is documented to modify the concentration of co-administered medicines that are metabolized by Cytochrome P450 (CYP) enzymes. Deferasirox increases the systemic exposure of CYP2C8 substrates (e.g., repaglinide) and CYP1A2 substrates (e.g., theophylline), while it decreases the exposure of CYP3A4 substrates (e.g., midazolam). An exposure increase of Busulfan is also officially stated.

Additionally, a pharmacodynamic interaction exists with drugs that have ulcerogenic or hemorrhagic potential (such as non-steroidal anti-inflammatory drugs or anticoagulants), which increases the documented risk of gastrointestinal bleeding. Co-administration with nephrotoxic drugs may increase the risk of acute renal failure. Official guidance notes that the risk of gastrointestinal hemorrhage is heightened in elderly patients with pre-existing risk factors when co-administered with ulcerogenic agents.

Targeted Chelation of Labile Iron

Deferasirox functions as a high-affinity tridentate ligand, chemically seeking out and binding specifically to the toxic, unbound ferric iron (Fe^3+) found circulating in the plasma (NTBI) and accumulating inside cells (LPI). This action removes the metal ion that acts as the catalyst for cellular damage and facilitates the transfer of accumulated intracellular iron from parenchymal cells.

---

Neutralizing Oxidative Stress and Modulating Cellular Resilience

By capturing the free ferric iron, Deferasirox immediately interrupts the biochemical pathway that generates highly damaging Reactive Oxygen Species (ROS), thereby limiting the molecular events that precipitate cellular damage caused by oxidative stress. This primary mechanism, supported by the drug’s secondary antioxidant properties, contributes to the maintenance of normal physiological signaling within cells.

---

Forming and Eliminating a Stable Iron Complex

Once the inert, stable, two-to-one iron-drug complex is formed, it is predominantly processed by the biliary system and excreted from the body via the feces. This mechanism facilitates systemic clearance, leading to a negative iron balance that results in a sustained reduction in total systemic iron.

How to Use Deferasirox

Deferasirox is prescribed as an oral medication and is available in two distinct dosage forms: tablets for oral suspension and film-coated tablets. The medication is taken once daily at approximately the same time each day to maintain a consistent systemic level. The dose is customized for each patient on a milligram per kilogram (mg/kg) body weight basis and is not static; it is subject to periodic adjustment (titration) by a healthcare professional, typically every three to six months, based on the assessment of the patient’s iron overload status.

Administration depends critically on the formulation used:

---

Form-Specific Administration Rules

Dosage Form	Meal Timing Requirement	Preparation and Intake	Special Restrictions
Tablets for Oral Suspension	Must be taken on an empty stomach, at least 30 minutes before food.	Must be fully dispersed by stirring in a small volume of water, orange juice, or apple juice; consume immediately.	Do not chew or swallow whole.
Film-Coated Tablets	May be taken on an empty stomach or with a light meal.	Must be swallowed whole with water.	Do not crush or chew.

---

The standard adult starting dose for the film-coated tablets is generally 14 mg/kg once daily for transfusional iron overload, with a maximum dose typically not exceeding 28 mg/kg per day. For certain patient populations, such as those with moderate hepatic or significant renal impairment, the starting dose is often reduced by 50% to account for changes in drug processing, reflecting label guidance on population-specific administration. If a dose is missed, it should be taken as soon as it is remembered on the same day; the following day's dose should not be doubled.

Evidence for Managing Iron Overload from Blood Transfusions

Research examining Deferasirox for iron overload resulting from repeated blood transfusions (transfusional hemosiderosis) relies on large Randomized Controlled Trials (RCTs) across adult and pediatric patients (aged ge 2 years). These studies examine changes in iron biomarkers like Liver Iron Concentration (LIC) and Serum Ferritin. Pivotal trials collected data that was studied for comparison to a previous standard of care, examining whether the medicine met study-defined parameters for iron levels. Research also examined specific cohorts with iron accumulation in the heart (myocardial siderosis). However, certain conditions like Myelodysplastic Syndromes (MDS) were studied through less uniform pooled analyses.

---

Evidence for Non-Transfusion-Dependent Thalassemias (NTDT)

Separate evidence was studied for patients with NTDT syndromes who accumulate iron through intestinal absorption. This research is rooted in randomized, placebo-controlled Phase II studies enrolling patients ge 10 years of age. These studies examined changes in LIC and serum ferritin over approximately one year. The overall body of evidence is limited compared to the transfusion-dependent group, and limited comparative evidence is available because older treatments were often not prospectively investigated in controlled clinical trials for this specific population.

---

Long-Term Studies and Durability of Response

Research explores outcomes over longer periods through open-label extension protocols. These studies monitor long-term patterns related to iron levels and organ function. However, long-term effects are not fully established and certainty remains low regarding endpoints like overall survival. Comprehensive data over decades are still emerging.

---

Research in Specific Patient Groups

Findings for some distinct groups, such as pediatric patients (ge 2 years) and older adults (ge 65 years), often derive from pooled analyses that combine data from several studies. This means the evidence quality varies across studies for these subgroups, and subgroup findings are uncertain compared to the main trial populations.

---

Evidence Gaps and Areas of Uncertainty

Research highlights what is known and what is still uncertain. Key limitations include follow-up durations were limited in core trials, meaning research is ongoing to understand the impact over many years. Data for certain groups remain insufficient, including very young children, and research does not determine whether an individual will respond similarly, as findings describe group patterns, not personal outcomes.

Common questions about Deferasirox (FAQ)

Q: Is Deferasirox the same as Desferal (Deferoxamine)?

Deferasirox and Desferal (Deferoxamine) are both medicines belonging to the class of iron chelators, which help remove excess iron from the body. Official drug information indicates that Deferasirox is a newer, synthetic medicine taken orally. Deferoxamine, on the other hand, is a different compound that is typically administered by injection or infusion.

Q: Does Deferasirox affect the kidneys or liver?

Yes, official drug information includes warnings and precautions related to both the kidneys and liver. The medicine has been associated with increases in creatinine, which indicates potential kidney issues, and is also linked to the risk of hepatic injury or liver failure. Monitoring of kidney and liver function tests is described in official documentation as a necessary precaution before starting and periodically throughout therapy.

Q: Is it true that Deferasirox might cause issues with eyesight or hearing?

Official documentation notes that Deferasirox is associated with potential issues related to both hearing and eyesight. Hearing loss is listed as a common reaction in safety summaries, and vision problems are also reported. Regulatory documents state that monitoring for any changes in hearing or vision is necessary as a precaution.

Q: What types of foods or drinks should people avoid while on Deferasirox?

Regulatory guidance strictly advises avoiding the simultaneous use of aluminum-containing antacid preparations. This combination has been shown to potentially increase the systemic exposure to aluminum. While no other specific food or drink is strictly contraindicated, official documents provide detailed instructions on the administration timing relative to meals, which varies by the tablet form.

Q: Can Deferasirox be taken alongside vitamins or mineral supplements?

Official prescribing information advises that taking the medicine with iron supplements should be avoided. The regulatory guidance for general vitamins or non-iron mineral supplements is not explicitly defined as a contraindication. Because the medicine is known to interact with certain enzymes that process many other substances, official prescribing information advises consultation with a healthcare professional regarding combined use.

Q: Is Deferasirox used for iron overload from other causes besides blood transfusions?

Yes, the medicine is officially indicated for treating chronic iron overload caused by repeated blood transfusions (transfusional hemosiderosis). It is also approved for treating chronic iron overload in patients with non-transfusion-dependent thalassemia (NTDT) syndromes who meet specific criteria outlined in the regulatory label.

Q: What are some less common but serious side effects of Deferasirox?

Safety documents list serious adverse reactions that occur less frequently than the most common side effects. These include severe health issues such as acute kidney failure and hepatic failure. The medicine has also been associated with severe skin reactions and internal bleeding (gastrointestinal haemorrhage).

Q: How frequently are blood tests usually performed when starting Deferasirox?

Official prescribing information recommends frequent monitoring of blood work to check on iron levels, as well as kidney and liver function. These tests are typically performed at least monthly throughout the duration of the treatment. In certain circumstances, such as at the start of therapy or during an acute illness, monitoring may be advised more frequently.

Q: Are there any official warnings or precautions about Deferasirox use?

Yes, official prescribing information includes several major Warnings and Precautions that require monitoring. These address the potential for issues with the kidneys (acute injury), the liver (hepatic toxicity), the gastrointestinal tract (hemorrhage), and the bone marrow (suppression). Official guidance outlines these risks and the necessary patient monitoring.

Q: Does Deferasirox change the color of urine or other body fluids?

Some official patient information indicates that a change in urine color can occur while taking the medicine. This may be a reddish-brown color and is related to the process of iron chelation and elimination from the body. This change is an expected observation noted in some official guidance, related to the iron chelation process.

Q: How long does it typically take for Deferasirox to start reducing iron levels?

Regulatory documents do not specify a quick onset of action, such as a number of days or weeks. Clinical trials used to demonstrate efficacy typically measure sustained changes in iron levels, such as Liver Iron Concentration (LIC) and serum ferritin, over a period of approximately one year.

Q: Is the medication often prescribed under its generic name or a brand name?

Deferasirox is the generic name for the active ingredient. The medication has been prescribed under two main brand names: Exjade, for the dispersible tablets, and Jadenu, for the film-coated tablets. The drug is also available as a generic formulation.

Q: Is it safe to drive while taking Deferasirox?

Official product information advises that the ability to drive or operate machinery might be affected because side effects, including dizziness and headache, are common. Because of these potential effects, professional guidance suggests being aware of how the medicine affects the individual before performing tasks like driving.

Q: Does Deferasirox interact with herbal supplements?

Official documents do not list specific herbal supplements as prohibited. However, the medicine interacts with certain liver enzymes (CYP and UGT) that also process many herbal and dietary supplements. This suggests a possibility that the effects of the medicine or the supplement could be altered. Official prescribing information advises consulting a healthcare professional regarding potential interactions.

Q: Can Deferasirox be split, crushed, or chewed?

Administration rules depend entirely on the tablet form. Tablets for oral suspension must not be chewed or swallowed whole, as they must be dispersed in liquid. Film-coated tablets must be swallowed whole, but official guidance states they may be crushed and mixed with soft food, such as applesauce, if swallowing is difficult.

Q: Are there any known interactions between Deferasirox and alcohol?

Official drug information notes that the medicine increases the risk of both liver toxicity and gastrointestinal bleeding. Due to the established risks of liver toxicity and gastrointestinal bleeding, official prescribing information advises consulting a healthcare professional regarding alcohol consumption.

Q: What happens if a child accidentally swallows a lot of Deferasirox?

Official regulatory guidance on overdose advises that if an accidental overdose occurs, immediate medical assistance is necessary. This may involve contacting a poison control center or emergency services. Overdoses have been associated with both hepatic and renal abnormalities.

Q: Can Deferasirox affect blood sugar levels?

Official drug interaction information notes that Deferasirox can increase the systemic exposure of the medicine repaglinide, which is used to manage diabetes. Official guidance notes that careful monitoring of blood glucose levels is necessary if the two medicines are co-administered.

Q: Does Deferasirox work for all types of iron overload?

No. Official indications specify that the medicine is only used for certain types of chronic iron overload. These are specifically those due to repeated blood transfusions (transfusional hemosiderosis) and iron overload in patients with Non-Transfusion-Dependent Thalassemias (NTDT) who meet certain clinical criteria.

Q: Can Deferasirox affect fertility in men or women?

Official regulatory information includes a section for people of reproductive potential, and animal studies have indicated a potential for impaired fertility. Data on the effects on human fertility are not fully established, according to official labeling.

Q: What is the purpose of the initial blood work before starting Deferasirox?

The initial blood work is required to establish a baseline assessment of key health indicators, particularly kidney and liver function. This is necessary because the medicine is strictly prohibited in patients with severe impairment of these organs, and the starting dose may need to be adjusted in those with moderate impairment.

Q: Is Deferasirox associated with any changes in mood or sleep?

Official safety summaries mention side effects that relate to the nervous system. Common effects include headache and dizziness. Less commonly, some official patient information has noted changes such as sleep problems and anxiety.

How to Store and Dispose of Deferasirox?

Deferasirox must be stored strictly according to regulatory standards to maintain its effectiveness. The medication should be kept at a controlled room temperature of 25 C (77 F), allowing brief excursions between 15 C to 30 C (59 F to 86 F). Tablets must be protected from moisture and stored in the original, closed container.

Handling and Disposal

It is mandatory to keep Deferasirox out of the sight and reach of children. For disposal, unused or expired medicine must not be thrown into household waste or wastewater. Patients must consult a healthcare professional or pharmacist to dispose of the product in accordance with local requirements.